Menu Close

Congrats to Drs. Adrian V. Lee, Steffi Oesterreich, and Daniel D. Brown for their contributions to the latest Nature publication: A dependency map enhanced with next-generation 3D cancer models!

Congrats to Drs. Adrian V. Lee, Steffi Oesterreich, and Daniel D. Brown for their contributions to the latest Nature publication: A dependency map enhanced with next-generation 3D cancer models!
https://www.nature.com/articles/s41586-026-10843-7

This work was a collaboration with the Broad Institute of MIT and Harvard. Breast cancer patient-derived organoid (PDO) models were developed by Daniel Brown in the Institute for Precision Medicine in collaboration with the Lee-Oesterreich lab, and some of these PDO models were provided to the Broad Institute. The Broad team ran genome-scale CRISPR screens across 147 organoid and spheroid models spanning 10 cancer types, expanding the Cancer Dependency Map (DepMap) into tumor subtypes traditional cell lines simply don’t capture. These models preserve transcriptional programs that get silenced in 2D culture (like the PDAC-classical/MUC program in GI organoids), and oncogene dependency itself can be model-dependent. Model choice shapes the biology we’re able to see.

This manuscript was one of three companion papers published together in Nature, all validating patient-derived 3D cancer models as the next generation of preclinical tools.

Our contribution to this work was supported in part by NIH R01CA252378 through the National Cancer Institute (NCI) Oncology Models Forum, grateful for that support in helping make this collaboration possible.

This seminal paper is published alongside two outstanding companion papers:
Herranz-Ors et al. (Wellcome Sanger Institute), “A tumour-derived organoid biobank maps cancer gene dependencies” — 256 clinically annotated organoids across five GI/gynecologic cancers, with genome-wide CRISPR dependency screens on 162 of them.

ElHarouni et al., “A compendium of next-generation patient-derived models for diverse cancers” — the Human Cancer Models Initiative’s landmark 665-model resource across 25 cancer types.

Together, these three papers make a compelling, converging case that organoids and related New Approach Methodologies (NAMs) can faithfully recapitulate tumor biology at a scale sufficient for systematic target discovery, not just as a nice complement to cell lines, but as tools that reveal biology cell lines miss entirely. That’s the bet we’ve made with the Organoid Research Core here at Pitt, and it’s exciting to see it borne out across multiple independent efforts at once.

A dependency map enhanced with next-generation 3D cancer models | Nature
A tumour-derived organoid biobank maps cancer gene dependencies | Nature
A compendium of next-generation patient-derived models for diverse cancers | Nature

New Publication from Dr. Julia Foldi & the L/O Lab: personalized ctDNA in metastatic ILC

Julia Foldi MD and colleagues from the Lee-Oesterreich laboratory collaborated with Natera Inc to report on retrospective analysis of real-world data in 66 patients with metastatic ILC using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera). Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.

https://pubmed.ncbi.nlm.nih.gov/40324116

New publication in JAMA Surgery by Neil Carleton!

Congrats to Neil, Adrian, and Steffi on their new publication in JAMA Surgery! They led a nonrandomized trial evaluating a “nudge” intervention embedded in the electronic health record to decrease use of low-value axillary surgery for older patients with ER+ breast cancer. The nudge was widely successful and decreased use of SLNB by about 50% over the study period. This study included a strong collaborative component with researchers from breast surgical oncology, general internal medicine, statisticians, and AI/ML experts. Full link to the paper can be found here:

https://jamanetwork.com/journals/jamasurgery/fullarticle/2821213

Our EstroGene browser is launched to the public!

We are pleased to introduce the EstroGene Project -a comprehensive multi-omic NGS database focusing on estrogen receptor function in breast cancer. It aims to document and integrate the majority of publicly available estrogen-stimulated next generation sequencing data sets (including RNA-seq, microarray, ChIP-seq, ATAC-seq, ChIA-PET, Hi-C, GRO-seq, etc), and establish a comprehensive database to allow users’ customized data mining and visualization. We have curated 136 published NGS data sets from 2004-2022 across 19 breast cancer cell lines and generated a browser for simplified queries.

Features of EstroGene:

-A uniformly processed and crowd-sourced multi-omic database with detailed experimental documentation summary.

-A browser allowing single gene-based visualization of E2-induced expressional changes and ER proximal binding at users’ selected genes of interest.

-A browser supporting statistical cutoff-based gene list query function to export genes regulated by E2 under users’ defined contexts.

-An ER and breast cancer-centered database for dissecting the biological and technical diversity and variation of estrogen receptor-relevant NGS experiments and the confound ER regulomes in breast cancer.

We have summarized all of the curated datasets in this google form. We are crowd-sourcing additional datasets that may not be available in the public domain but are available within laboratories. If you have such a dataset please don’t hesitate to fill in the google form and we will contact you back.

We would appreciate it if you could operate the website and give us feedbacks to improve it and continue notify us about new data sets via the google form.

The BioRxiv manuscript of this project will be deposit after receiving feedbacks from the research community!

For any queries please email Nadine Ryan (ryann@upmc.edu)

Dr. Steffi Oesterreich and the lab’s latest collaborative publication in JNCI featured in the Pittsburgh Post Gazette!

Research publication: Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer

https://www.post-gazette.com/news/health/2022/10/17/breast-cancer-invasive-lobular-cancer-ilc-idc-steffi-oesterreich/stories/202210170073

Congrats to Neil Carleton on his new publication in Nature Reviews Clinical Oncology!

Congrats to lab member Neil Carleton and surgeon / lab collaborator Dr. Priscilla McAuliffe on their recent publication in Nature Reviews Clinical Oncology! This comment explores how chronological age cutoffs in clinical oncology guidelines are defined. Using the case of breast cancer in older women, the authors discuss why the age at which individuals transition from ‘younger’ to ‘older’ has been defined in a heterogeneous, unstandardized, arbitrary and disparate manner. 

Read the full article here: https://www.nature.com/articles/s41571-022-00684-4.